A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
← catalyst calendarNCT05779592 · readout in 867 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Ono Pharmaceutical Co., Ltd..
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
400estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-23 | actual | When the study began enrolling |
| Primary completion | 2029-01-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscle-invasive Urothelial Carcinoma
Primary outcomes
what the primary-completion date above is the date OFDisease-free survival (DFS)
measured Up to 4 years
Non-urothelial tract recurrence free survival (NUTRFS)
measured Up to 4 years
Number of participants with adverse events (AEs)
measured Up to 4 years
Number of participants with treatment-related adverse events (TRAEs)
measured Up to 4 years
Actual treatment status: dosing frequency
measured Up to 4 years
Actual treatment status: treatment duration
measured Up to 4 years
Actual treatment status: treatment completion rate
measured Up to 4 years
Actual treatment status: reason for discontinuation
measured Up to 4 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed